proglumide Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Proglumide (Milid) is a drug that inhibits gastrointestinal motility and reduces gastric secretions. It acts as a cholecystokinin antagonist, which blocks both the CCKA and CCKB subtypes. It was used mainly in the treatment of stomach ulcers, although it has now been largely replaced by newer drugs for this application.   Wikipedia

Chemistry

  • SMILES: Cn1c(N)c(NC(=O)NCCN)c[n+]1CC2=C(N3[C@H](SC2)[C@H](NC(=O)\C(=N/OC(C)(C)C(=O)[O-])\c4nsc(N)n4)C3=O)C(=O)O
  • InChIKey: JHFNIHVVXRKLEF-DCZLAGFPSA-N
  • Mol. Mass: 666.7
  • ALogP: -3.9
  • ChEMBL Molecules:
    ceftolozane  
    ceftolozane sulfate  
    proglumide  
More Chemistry

Pharmacology

Alternative names

binoside | cr 242 | cr-242 | dl-proglumide | m-001 | milid | nulsa | proglumide | promide | w 5219 | w-5219 | xylamide

Organizations (2)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Fibrosis (Phase 1/Phase 2)

Influenza, Human (Phase 2)

Liver Cirrhosis (Early Phase 1)

Non-alcoholic Fatty Liver Disease (Phase 1)

Pain (Phase 1/Phase 2)

Pancreatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue